{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:57:22Z","timestamp":1787003842961,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science Centre, Poland","award":["SONATA, 2020\/39\/D\/NZ5\/02330"],"award-info":[{"award-number":["SONATA, 2020\/39\/D\/NZ5\/02330"]}]},{"DOI":"10.13039\/501100004421","name":"Warsaw University of Technology","doi-asserted-by":"crossref","award":["POSTDOC PW V"],"award-info":[{"award-number":["POSTDOC PW V"]}],"id":[{"id":"10.13039\/501100004421","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45586-y","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:54:47Z","timestamp":1774295687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive transcriptomic characterization of two melanoma cell lines with acquired dual resistance to BRAF and MEK inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Tomasz","family":"Kujawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Simiczyjew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gambin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Kobiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"4","key":"45586_CR1","first-page":"63","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P. & Barsouk, A. Epidemiol. Melanoma Med. Sci. ;9(4):63. (2021).","journal-title":"Epidemiol. Melanoma Med. Sci."},{"key":"45586_CR2","doi-asserted-by":"publisher","first-page":"104276","DOI":"10.1016\/j.critrevonc.2024.104276","volume":"196","author":"A Boutros","year":"2024","unstructured":"Boutros, A. et al. The treatment of advanced melanoma: Current approaches and new challenges. Crit. Rev. Oncol. Hematol. 196, 104276 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"45586_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/jid.2014.366","volume":"135","author":"AE Siroy","year":"2015","unstructured":"Siroy, A. E. et al. Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J. Invest. Dermatol. 135 (2), 508\u2013515 (2015).","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"45586_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl. J. Med. 381 (7), 626\u2013636 (2019).","journal-title":"N Engl. J. Med."},{"key":"45586_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","volume":"62","author":"SJ Welsh","year":"2016","unstructured":"Welsh, S. J., Rizos, H., Scolyer, R. A. & Long, G. V. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Eur. J. Cancer. 62, 76\u201385 (2016).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"45586_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","volume":"27","author":"G Moriceau","year":"2015","unstructured":"Moriceau, G. et al. Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF\/MEK Cotargeting but Result in Melanoma Drug Addiction. Cancer Cell. 27 (2), 240\u2013256 (2015).","journal-title":"Cancer Cell."},{"issue":"1","key":"45586_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41231-022-00133-5","volume":"8","author":"V Belli","year":"2023","unstructured":"Belli, V. et al. Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. Transl Med. Commun. 8 (1), 3 (2023).","journal-title":"Transl Med. Commun."},{"issue":"1","key":"45586_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12964-024-01788-3","volume":"22","author":"M Kot","year":"2024","unstructured":"Kot, M. et al. Characterization of two melanoma cell lines resistant to BRAF\/MEK inhibitors (vemurafenib and cobimetinib). Cell. Commun. Signal. 22 (1), 410 (2024).","journal-title":"Cell. Commun. Signal."},{"issue":"1","key":"45586_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12964-025-02452-0","volume":"23","author":"A Simiczyjew","year":"2025","unstructured":"Simiczyjew, A. et al. Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells. Cell. Commun. Signal. 23 (1), 449 (2025).","journal-title":"Cell. Commun. Signal."},{"issue":"17","key":"45586_CR10","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34 (17), i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"issue":"1","key":"45586_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma Oxf. Engl. 29 (1), 15\u201321 (2013).","journal-title":"Bioinforma Oxf. Engl."},{"issue":"2","key":"45586_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","volume":"32","author":"K Okonechnikov","year":"2016","unstructured":"Okonechnikov, K., Conesa, A. & Garc\u00eda-Alcalde, F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32 (2), 292\u2013294 (2016).","journal-title":"Bioinformatics"},{"issue":"10","key":"45586_CR13","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41 (10), e108 (2013).","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"45586_CR14","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","volume":"4","author":"S Durinck","year":"2009","unstructured":"Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt. Nat. Protoc. 4 (8), 1184\u20131191 (2009).","journal-title":"Nat. Protoc."},{"issue":"2","key":"45586_CR15","doi-asserted-by":"publisher","first-page":"gkaf018","DOI":"10.1093\/nar\/gkaf018","volume":"53","author":"Y Chen","year":"2025","unstructured":"Chen, Y., Chen, L., Lun, A. T. L., Baldoni, P. L. & Smyth, G. K. edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Res. 53 (2), gkaf018 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"45586_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15 (12), 550 (2014).","journal-title":"Genome Biol."},{"key":"45586_CR17","doi-asserted-by":"crossref","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The Innovation [Internet]. [cited 2025 Jun 12];2(3). (2021). Available from: https:\/\/www.cell.com\/the-innovation\/abstract\/S2666-6758(21)00066-7","DOI":"10.1016\/j.xinn.2021.100141"},{"issue":"12","key":"45586_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27 (12), 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"issue":"1","key":"45586_CR19","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"P Badia-i-Mompel","year":"2022","unstructured":"Badia-i-Mompel, P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinforma Adv. 2 (1), vbac016 (2022).","journal-title":"Bioinforma Adv."},{"issue":"3","key":"45586_CR20","doi-asserted-by":"publisher","first-page":"e9923","DOI":"10.15252\/msb.20209923","volume":"17","author":"D T\u00fcrei","year":"2021","unstructured":"T\u00fcrei, D. et al. Integrated intra\u2010 and intercellular signaling knowledge for multicellular omics analysis. Mol. Syst. Biol. 17 (3), e9923 (2021).","journal-title":"Mol. Syst. Biol."},{"key":"45586_CR21","doi-asserted-by":"publisher","unstructured":"Wickham, H. ggplot2 [Internet]. Cham: Springer International Publishing; [cited 2025 Nov 26]. (Use R!). Available from: http:\/\/link.springer.com\/ (2016). https:\/\/doi.org\/10.1007\/978-3-319-24277-4","DOI":"10.1007\/978-3-319-24277-4"},{"issue":"13","key":"45586_CR22","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.7150\/thno.42096","volume":"10","author":"X Ding","year":"2020","unstructured":"Ding, X. et al. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase. Theranostics 10 (13), 6048\u20136060 (2020).","journal-title":"Theranostics"},{"key":"45586_CR23","doi-asserted-by":"publisher","first-page":"116618","DOI":"10.1016\/j.biopha.2024.116618","volume":"175","author":"S Janciauskiene","year":"2024","unstructured":"Janciauskiene, S., Lechowicz, U., Pelc, M., Olejnicka, B. & Chorostowska-Wynimko, J. Diagnostic and therapeutic value of human serpin family proteins. Biomed. Pharmacother. 175, 116618 (2024).","journal-title":"Biomed. Pharmacother"},{"key":"45586_CR24","doi-asserted-by":"publisher","unstructured":"O\u2019Toole, K. T. et al. Characterization of the BRAF interactome identifies BRAF V600E <=>TP53 interaction in melanoma. bioRxiv 2025.06.20.660711; doi: https:\/\/doi.org\/10.1101\/2025.06.20.660711","DOI":"10.1101\/2025.06.20.660711"},{"key":"45586_CR25","doi-asserted-by":"crossref","unstructured":"Pandya, P. et al. p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration. Cells [Internet]. 2022 [cited 2025 Nov 25];11(3). (2073). Available from: https:\/\/www.mdpi.com\/-4409\/11\/3\/405.","DOI":"10.3390\/cells11030405"},{"issue":"1","key":"45586_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pcmr.12180","volume":"27","author":"NF Box","year":"2014","unstructured":"Box, N. F., Vukmer, T. O. & Terzian, T. Targeting p53 in melanoma. Pigment Cell. Melanoma Res. 27 (1), 8\u201310 (2014).","journal-title":"Pigment Cell. Melanoma Res."},{"issue":"1","key":"45586_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal. Transduct. Target. Ther. 8 (1), 455 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"45586_CR28","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1038\/s41467-020-19075-3","volume":"11","author":"R Tripathi","year":"2020","unstructured":"Tripathi, R. et al. Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling. Nat. Commun. 11, 5463 (2020).","journal-title":"Nat. Commun."},{"key":"45586_CR29","doi-asserted-by":"publisher","unstructured":"McRee, S. K., Bayer, A. L., Pietruska, J., Tsichlis, P. N. & Hinds, P. W. AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis [Internet]. bioRxiv; 2023 [cited 2025 Jul 25]. p. 2023.08.24.554685. Available from: https:\/\/www.biorxiv.org\/content\/https:\/\/doi.org\/10.1101\/2023.08.24.554685v1","DOI":"10.1101\/2023.08.24.554685v1"},{"issue":"17","key":"45586_CR30","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1038\/s41388-017-0061-7","volume":"37","author":"Y Yu","year":"2018","unstructured":"Yu, Y., Dai, M., Lu, A., Yu, E. & Merlino, G. PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation. Oncogene 37 (17), 2225\u20132236 (2018).","journal-title":"Oncogene"},{"issue":"16","key":"45586_CR31","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1038\/s44319-025-00521-6","volume":"26","author":"J Yu","year":"2025","unstructured":"Yu, J. et al. Transcriptome-wide decoding the roles of aberrant splicing in melanoma MAPK-targeted resistance evolution. EMBO Rep. 26 (16), 4180\u20134196 (2025).","journal-title":"EMBO Rep."},{"issue":"3","key":"45586_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1535-7163.MCT-23-0474","volume":"23","author":"GL Parkman","year":"2024","unstructured":"Parkman, G. L. et al. Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression. Mol. Cancer Ther. 23 (3), 301\u2013315 (2024).","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"45586_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41467-022-28801-y","volume":"13","author":"C Capparelli","year":"2022","unstructured":"Capparelli, C. et al. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nat. Commun. 13 (1), 1381 (2022).","journal-title":"Nat. Commun."},{"issue":"4","key":"45586_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow, F. et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell 174 (4), 843\u2013855e19 (2018).","journal-title":"Cell"},{"issue":"24","key":"45586_CR35","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","volume":"37","author":"Q Zuo","year":"2018","unstructured":"Zuo, Q. et al. AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene 37 (24), 3275\u20133289 (2018).","journal-title":"Oncogene"},{"issue":"1","key":"45586_CR36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41698-021-00207-x","volume":"5","author":"Y Qin","year":"2021","unstructured":"Qin, Y. et al. PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN. Npj Precis Oncol. 5 (1), 68 (2021).","journal-title":"Npj Precis Oncol."},{"issue":"7","key":"45586_CR37","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","volume":"71","author":"KHT Paraiso","year":"2011","unstructured":"Paraiso, K. H. T. et al. PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. Cancer Res. 71 (7), 2750\u20132760 (2011).","journal-title":"Cancer Res."},{"issue":"1","key":"45586_CR38","first-page":"56","volume":"19","author":"M Schmidt","year":"2022","unstructured":"Schmidt, M. et al. Single-cell trajectories of melanoma cell resistance to targeted treatment. Cancer Biol. Med. 19 (1), 56\u201373 (2022).","journal-title":"Cancer Biol. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45586-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:02:13Z","timestamp":1778760133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45586"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45586-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14775"}}